DataString Consulting Company Logo
DataString Consulting Company Logo
Odevixibat Market
Home»Recent Reports»Odevixibat Market

Odevixibat Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802171, Published - April 2025

Segmented in Patients (Pediatric, Adult), Therapeutic Application (Progressive Familial Intrahepatic Cholestasis, Biliary Atresia, Alagille Syndrome, Others), Distribution Channel and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Odevixibat Market Outlook

The market, for Odevixibat was estimated at $291.5 million in 2024; and it is anticipated to increase to $418.2 million by 2030 with projections indicating a growth to around $564.9 million by 2035. This expansion represents a compound annual growth rate (CAGR) of 6.2% over the forecast period. The progression in Odevixibats market worth underlines its increasingly significant role within the pharmaceuticals sector. One of the critical propellants of this advancement is an escalating international demand owing to its pivotal role in treating rare gastrointestinal diseases. The ongoing relevance of Odevixibat can be accredited to substantial advances in healthcare services, burgeoning investments in research & development, and escalating awareness about the potency of cutting-edge therapeutics. These influencing factors collectively contribute to the prevalence of Odevixibat in the market and are anticipated to continue bolstering its demand in upcoming years.


Odevixibat is a distinguished therapeutic drug primarily known for its role in tackling progressive familial intrahepatic cholestasis (PFIC) and other rare pediatric cholestatic liver diseases. Its unique features include its innovative mechanism of actiontargeting the ileal bile acid transporter (IBAT), resulting in reduced reabsorption of bile acids.


Market Size Forecast & Key Insights

2019
$291M2024
2029
$531M2034

Absolute Growth Opportunity = $240M

The Odevixibat market is projected to grow from $291.5 million in 2024 to $531 million in 2034. This represents a CAGR of 6.2%, reflecting rising demand across Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC), Management of Alagille Syndrome and Therapy for Biliary Atresia.

The Odevixibat market is set to add $240 million between 2024 and 2034, with manufacturer targeting Biliary Atresia & Alagille Syndrome Therapeutic Application projected to gain a larger market share.

With Expanding role in progressive familial intrahepatic cholestasis treatment, and Broadening applications in cholestatic liver diseases, Odevixibat market to expand 82% between 2024 and 2034.

Opportunities in the Odevixibat Market

Fueling Global Market Expansion through Strategic Collaborations

The growth trajectory of Odevixibat is promising in emerging markets, particularly in Asia. Strengthening strategic collaborations with local partners and regulatory authorities could accelerate the availability and awareness of Odevixibat.

Odevixibats Potential in Pioneering Treatments and Technological Advancements in Drug Delivery

As a novel, first-in-class treatment, Odevixibat has a promising, untapped to dominate the market for progressive familial intrahepatic cholestasis . With minimal competition and pressing unmet patient needs, incorporating Odevixibat into mainstream patient-care could provide relief to many patients suffering from this rare, life-threatening condition.

The pharmaceutical industry is exponentially benefiting from technological advancements in drug delivery systems. With Odevixibat, There is an for innovation utilizing these advancements to expand the drugs application horizon. For example, more precise, targeted delivery systems could enhance the efficiency and effectiveness of Odevixibat, dramatically improving patient outcomes.

Growth Opportunities in North America and Europe

Europe Outlook

The European sector presents a robust market for Odevixibat, with an increasing number of recognized uses in treating Alagille syndrome and biliary atresia. The robust pharmaceutical framework, coupled with high awareness levels about rare diseases and their treatment, propels the demand for Odevixibat in this region. Top opportunities in Europe revolve around expanding approved applications for the drug and capitalizing on unmet medical needs. Factors such as the rise in extensive healthcare systems and significant increase in R&D initiatives emphasize the need for Odevixibat, thereby driving its market growth.

North America Outlook

In the North American market, Odevixibat exhibits a significant scope with its increasing prominence in the pharmaceutical sector. This growth is predominantly driven by extensive research and growing demand in the treatment of PFIC and other cholestatic liver diseases. Consequently, top opportunities lie in clinical developments and strategic partnerships with research institutions. The presence of robust pharmaceutical industries and health infrastructure further fuels the demand in this region. However, the competitive landscape is aggressively becoming denser with companies investing more in research and development activities to innovative treatments. Advanced healthcare services and high prevalence of rare and chronic diseases also act as powerful growth stimulants for Odevixibat in North America.

North America Outlook

In the North American market, Odevixibat exhibits a significant scope with its increasing prominence in the pharmaceutical sector. This growth is predominantly driven by extensive research and growing demand in the treatment of PFIC and other cholestatic liver diseases. Consequently, top opportunities lie in clinical developments and strategic partnerships with research institutions. The presence of robust pharmaceutical industries and health infrastructure further fuels the demand in this region. However, the competitive landscape is aggressively becoming denser with companies investing more in research and development activities to innovative treatments. Advanced healthcare services and high prevalence of rare and chronic diseases also act as powerful growth stimulants for Odevixibat in North America.

Europe Outlook

The European sector presents a robust market for Odevixibat, with an increasing number of recognized uses in treating Alagille syndrome and biliary atresia. The robust pharmaceutical framework, coupled with high awareness levels about rare diseases and their treatment, propels the demand for Odevixibat in this region. Top opportunities in Europe revolve around expanding approved applications for the drug and capitalizing on unmet medical needs. Factors such as the rise in extensive healthcare systems and significant increase in R&D initiatives emphasize the need for Odevixibat, thereby driving its market growth.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Japan, Germany, France, UK are expected to grow at 4.0% to 6.0% CAGR

2

Emerging Markets : Brazil, Philippines, South Africa are expected to grow at 7.1% to 8.6% CAGR

Market Analysis Chart

Odevixibat, a novel therapeutic compound, is making strides in the pharmaceutical industry. The primary market driver for Odevixibat comes from its highly specialized applications. Its use in treating rare pediatric cholestatic liver diseases opens a niche market that presents significant growth opportunities. Its distinctive targeting of the ileal bile acid transporter further cements its unique position, making it one of the few medications aimed at this specific treatment pathway.

Recent Developments and Technological Advancement

December 2024

Albireo Pharma, a prominent provider of Odevixibat, created a groundbreaking advancement by introducing a nano-formulation of the medication, ensuring a more efficient delivery system and improved patient compliance.

October 2024

Pharmaceutical major Johnson & Johnson announced a strategic partnership with Albireo Pharma to explore Odevixibat based therapeutics for liver diseases; a move expected to increase Odevixibats market reach.

July 2024

FDA approved a new indication for the use of Odevixibat in adult patients with primary biliary cholangitis, broadening the drugs application and increasing market potential for manufacturers like Albireo Pharma.

Odevixibat, a helpful drug in the treatment of progressive familial intrahepatic cholestasis , been making significant strides. There has been a noticeable surge in its demand, indicative of established market dynamics and novel technologies associated with its production and application.

Impact of Industry Transitions on the Odevixibat Market

As a core segment of the Pharmaceutical industry, the Odevixibat market develops in line with broader industry shifts. Over recent years, transitions such as Expansion in Therapeutic Domains and Regulatory Approvals Steering Growth have redefined priorities across the Pharmaceutical sector, influencing how the Odevixibat market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Expansion in Therapeutic Domains:

Odevixibat, a novel nonsystemic ileal bile acid transport inhibitor has been primarily associated with the pharmaceutical industry, delivering promising results in treating progressive familial intrahepatic cholestasis and Alagille syndrome. It significantly reverses the symptoms by modifying the bile acid flow, making it particularly effective against bile acidrelated disorders. The manufacturers strategic shift to pediatric cholestasis, where alternative treatments are scarce, demonstrates industry transitions resulting from the medicines unique mechanism. This transition has spurred developments within the pharmaceutical industry, as it has incentivized other players to venture into the realm of orphan diseases, thereby enriching the existing therapeutic apparatus.

2

Regulatory Approvals Steering Growth:

The FDA acceptance of Odevixibats New Drug Application and subsequent priority reviews serve as potent industry transitions. Such strides in regulatory recognitions have augmented the market share of Odevixibat, aiding the players who collaborate or are involved in the medicines production and distribution.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Odevixibat market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Expanding Role in Progressive Familial Intrahepatic Cholestasis Treatment, and Technological Advancements in Drug Delivery Systems

As a foremost medication, Odevixibat targets the treatment for Progressive Familial Intrahepatic Cholestasis , a rare genetic disorder. This therapeutic application is also poised to be a key market given the unmet medical needs and the shortage of effective treatments for PFIC. The expanding role of Odevixibat in PFIC promises to fuel its market demand, creating increased opportunities in the pharmaceutical sector.
Alongside the widening treatment applications, technological advancements in drug delivery systems are also set to influence Odevixibat market growth positively. The development and utilization of these advanced drug delivery methods, particularly suitable for Odevixibat, promise higher therapeutic efficacy and patient compliance, thereby serving as a crucial market growth facilitator.
Extensive research is also in progress to unravel the potential of Odevixibat in treating other cholestatic liver diseases. This broadening application spectrum underpins a significant market as it could also potentially offer an effective treatment alternative for a variety of liver diseases, thereby expanding the scope of Odevixibats industry reach.

Restraint: High Drug Development and Regulatory Costs

The development, testing, and regulation of new drugs such as Odevixibat present significant challenges. These high costs can limit the number of viable producers and subsequent market competition in the pharmaceutical industry. For instance, the expenses involved in exploratory studies, preclinical development, clinical testing and trials, and obtaining regulatory approval discourage potential players, consequently affecting the overall market trend for other stakeholders. This prohibitive financial base acts as a for the Odevixibat market, subsequently impacting the market demand and dynamics.

Challenge: Limited Awareness and Market Penetration

Despite the extraordinary potential of Odevixibat, the level of market awareness and penetration remains relatively low, especially in remote areas and developing nations. This limited exposure inhibits the market growth of Odevixibat and impacts the established market dynamics.

Supply Chain Landscape

Raw Material Providers

Cayman Chemical

MedKoo Biosciences

API & Intermediate Manufacturers

Albemarle Corporation

AstraZeneca

Formulation & Drug Developers
Mirum Pharmaceuticals / Albireo Pharma
End Consumer Industry
Gastroenterology / Pediatric Diseases
Raw Material Providers

Cayman Chemical

MedKoo Biosciences

API & Intermediate Manufacturers

Albemarle Corporation

AstraZeneca

Formulation & Drug Developers

Mirum Pharmaceuticals

Albireo Pharma

End Consumer Industry

Gastroenterology

Pediatric Diseases

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Progressive Familial Intrahepatic Cholestasis (PFIC)
Pharmaceuticals
Albireo Pharma
Focused on developing and commercializing novel bile acid modulators to treat orphan pediatric liver diseases
Biliary Atresia
Pharmaceuticals
Mirum Pharmaceuticals
Strategically focusing on pediatric rare liver diseases and advancing a new investigational drug into clinic for biliary atresia
Alagille Syndrome (ALGS)
Pharmaceuticals
Albireo Pharma
Expanding clinical trials and programs in rare cholestatic liver diseases to validate the effectiveness of Odevixibat

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Odevixibat market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Odevixibat in Management of Alagille Syndrome, Therapy for Biliary Atresia and Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Management of Alagille Syndrome

Odevixibat also plays an integral role in managing Alagille Syndrome, a genetic disorder that can adversely affect the liver, heart, and other parts of the body. Suppression of IBAT via Odevixibat aids in mitigating the accumulation of bile acid, thereby managing the symptoms of this syndrome.

Therapy for Biliary Atresia

Another application of Odevixibat lies in offering effective treatment for biliary atresia, a childhood disease of the liver. In these instances, the use of Odevixibat aids in improving the flow of bile by curbing the functioning of the IBAT. The therapeutic impact demonstrated by Odevixibat in treating this disease has further solidified its position within the pharmaceutical market.

Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Odevixibat is widely used in the treatment of PFIC, a genetic disorder that leads to progressive liver disease. It is an inhibitor of the ileal bile acid transporter and acts by reducing the reuptake of bile acids to the liver, thereby mitigating the effects of the disease. Key industry players like Albireo Pharma have gained significant market traction due to their focus on such innovative therapies.

Odevixibat vs. Substitutes:
Performance and Positioning Analysis

Odevixibat, unlike its alternatives, operates by inhibiting the ileal bile acid transporter, offering unique therapeutic benefits for cholestatic liver diseases. Its market position is prominent due to its potential to redefine patient outcomes

Odevixibat
  • Rifamycin /
  • Cholestyramine /
  • Phenobarbital
    High efficacy in treating progressive familial intrahepatic cholestasis, favorable safety profile
    Limited understanding of potential long-term side effects, narrow therapeutic application range
    Effective treatment, lower cost
    Potential side effects, not suitable for all types of the targeted condition

Odevixibat vs. Substitutes:
Performance and Positioning Analysis

Odevixibat

  • High efficacy in treating progressive familial intrahepatic cholestasis, favorable safety profile
  • Limited understanding of potential long-term side effects, narrow therapeutic application range

Rifamycin / Cholestyramine / Phenobarbital

  • Effective treatment, lower cost
  • Potential side effects, not suitable for all types of the targeted condition

Odevixibat, unlike its alternatives, operates by inhibiting the ileal bile acid transporter, offering unique therapeutic benefits for cholestatic liver diseases. Its market position is prominent due to its potential to redefine patient outcomes

Loading...

Research Methodology

This market research methodology defines the Odevixibat market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Odevixibat across Progressive Familial Intrahepatic Cholestasis, Biliary Atresia, and Alagille Syndrome Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Albireo Pharma Inc., Mirum Pharmaceuticals, and Novartis AG by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Providers, API & Intermediate Manufacturers, and Formulation & Drug Developers. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Odevixibat segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Providers (Cayman Chemical, MedKoo Biosciences), API & Intermediate Manufacturers (Albemarle Corporation, AstraZeneca), and Formulation & Drug Developers. Our parallel substitute analysis examines Rifamycin, Cholestyramine, and Phenobarbital, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Albireo Pharma Inc., Mirum Pharmaceuticals, and Novartis AG, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Odevixibat market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Odevixibat Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 309 million
Revenue Forecast in 2034USD 531 million
Growth RateCAGR of 6.2% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024291 million
Growth OpportunityUSD 240 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024291 million USD
Market Size 2027349 million USD
Market Size 2029393 million USD
Market Size 2030418 million USD
Market Size 2034531 million USD
Market Size 2035564 million USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredPatients, Therapeutic Application, Distribution Channel
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledAlbireo Pharma Inc., Mirum Pharmaceuticals, Novartis AG, AbbVie, Johnson & Johnson, Pfizer Inc., GlaxoSmithKline plc, Sanofi, Teva Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca PLC and Eli Lilly and Co.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Odevixibat Market Size, Opportunities & Strategic Insights, by Patients

4.1Pediatric
4.2Adult
Chapter 5

Odevixibat Market Size, Opportunities & Strategic Insights, by Therapeutic Application

5.1Progressive Familial Intrahepatic Cholestasis
5.2Biliary Atresia
5.3Alagille Syndrome
5.4Others
Chapter 6

Odevixibat Market Size, Opportunities & Strategic Insights, by Distribution Channel

6.1Hospital Pharmacies
6.2Retail Pharmacies
6.3Online Pharmacies
Chapter 7

Odevixibat Market, by Region

7.1North America Odevixibat Market Size, Opportunities, Key Trends & Strategic Insights
7.1.1U.S.
7.1.2Canada
7.2Europe Odevixibat Market Size, Opportunities, Key Trends & Strategic Insights
7.2.1Germany
7.2.2France
7.2.3UK
7.2.4Italy
7.2.5The Netherlands
7.2.6Rest of EU
7.3Asia Pacific Odevixibat Market Size, Opportunities, Key Trends & Strategic Insights
7.3.1China
7.3.2Japan
7.3.3South Korea
7.3.4India
7.3.5Australia
7.3.6Thailand
7.3.7Rest of APAC
7.4Middle East & Africa Odevixibat Market Size, Opportunities, Key Trends & Strategic Insights
7.4.1Saudi Arabia
7.4.2United Arab Emirates
7.4.3South Africa
7.4.4Rest of MEA
7.5Latin America Odevixibat Market Size, Opportunities, Key Trends & Strategic Insights
7.5.1Brazil
7.5.2Mexico
7.5.3Rest of LA
7.6CIS Odevixibat Market Size, Opportunities, Key Trends & Strategic Insights
7.6.1Russia
7.6.2Rest of CIS
Chapter 8

Competitive Landscape

8.1Competitive Dashboard & Market Share Analysis
8.2Company Profiles (Overview, Financials, Developments, SWOT)
8.2.1Albireo Pharma Inc.
8.2.2Mirum Pharmaceuticals
8.2.3Novartis AG
8.2.4AbbVie
8.2.5Johnson & Johnson
8.2.6Pfizer Inc.
8.2.7GlaxoSmithKline plc
8.2.8Sanofi
8.2.9Teva Pharmaceutical Industries Ltd.
8.2.10Amgen Inc.
8.2.11AstraZeneca PLC
8.2.12Eli Lilly and Co.